These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 3414786)

  • 61. Monoclonal glomerulopathy with features of cryoglobulinemic glomerulopathy in murine multiple myeloma model.
    Zhang PL; Herrera GA; Liu B
    Ultrastruct Pathol; 2020 Nov; 44(4-6):387-394. PubMed ID: 33135540
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Characterization of the role of Samsn1 loss in multiple myeloma development.
    Friend NL; Hewett DR; Panagopoulos V; Noll JE; Vandyke K; Mrozik KM; Fitter S; Zannettino ACW
    FASEB Bioadv; 2020 Sep; 2(9):554-572. PubMed ID: 32923989
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Mouse tumor susceptibility genes identify drug combinations for multiple myeloma.
    Zhang S; DuBois W; Zhang K; Simmons JK; Hughitt VK; Gorjifard S; Gaikwad S; Peat TJ; Mock BA
    J Cancer Metastasis Treat; 2020; 6():. PubMed ID: 32923678
    [TBL] [Abstract][Full Text] [Related]  

  • 64. GLIPR1 expression is reduced in multiple myeloma but is not a tumour suppressor in mice.
    Friend N; Noll JE; Opperman KS; Clark KC; Mrozik KM; Vandyke K; Hewett DR; Zannettino ACW
    PLoS One; 2020; 15(1):e0228408. PubMed ID: 31995627
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Myeloma Cells Down-Regulate Adiponectin in Bone Marrow Adipocytes Via TNF-Alpha.
    Morris EV; Suchacki KJ; Hocking J; Cartwright R; Sowman A; Gamez B; Lea R; Drake MT; Cawthorn WP; Edwards CM
    J Bone Miner Res; 2020 May; 35(5):942-955. PubMed ID: 31886918
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Transcriptomic profiling of the myeloma bone-lining niche reveals BMP signalling inhibition to improve bone disease.
    Gooding S; Olechnowicz SWZ; Morris EV; Armitage AE; Arezes J; Frost J; Repapi E; Edwards JR; Ashley N; Waugh C; Gray N; Martinez-Hackert E; Lim PJ; Pasricha SR; Knowles H; Mead AJ; Ramasamy K; Drakesmith H; Edwards CM
    Nat Commun; 2019 Oct; 10(1):4533. PubMed ID: 31586071
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The Use of Murine Models for Studying Mechanistic Insights of Genomic Instability in Multiple Myeloma.
    Vlummens P; De Veirman K; Menu E; De Bruyne E; Offner F; Vanderkerken K; Maes K
    Front Genet; 2019; 10():740. PubMed ID: 31475039
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Osteolytic disease in IL-6 and Myc dependent mouse model of human myeloma.
    Sun F; Cheng Y; Walsh SA; Acevedo MR; Jing X; Han SS; Pisano MD; Tomasson MH; Lichtenstein AK; Zhan F; Hari P; Janz S
    Haematologica; 2020 Mar; 105(3):e111-e115. PubMed ID: 31221780
    [No Abstract]   [Full Text] [Related]  

  • 69. What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between
    Bailly C; Gouard S; Guérard F; Chalopin B; Carlier T; Faivre-Chauvet A; Remaud-Le Saëc P; Bourgeois M; Chouin N; Rbah-Vidal L; Tripier R; Haddad F; Kraeber-Bodéré F; Bodet-Milin C; Chérel M
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31137758
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Immunotherapeutics in Multiple Myeloma: How Can Translational Mouse Models Help?
    Cooke RE; Koldej R; Ritchie D
    J Oncol; 2019; 2019():2186494. PubMed ID: 31093282
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Chronic intermittent hypoxia enhances disease progression in myeloma-resistant mice.
    Ali M; Kowkuntla S; Delloro DJ; Galambos C; Hathi D; Janz S; Shokeen M; Tripathi C; Xu H; Yuk J; Zhan F; Tomasson MH; Bates ML
    Am J Physiol Regul Integr Comp Physiol; 2019 May; 316(5):R678-R686. PubMed ID: 30892915
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Surgical thyroparathyroidectomy prevents progression of 5TGM1 murine multiple myeloma
    Zangari M; Yoo H; Shin IJ; Yoon D; Suva LJ
    J Bone Oncol; 2018 Sep; 12():19-22. PubMed ID: 29556454
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comparison of Immuno-PET of CD138 and PET imaging with
    Bailly C; Gouard S; Lacombe M; Remaud-Le Saëc P; Chalopin B; Bourgeois M; Chouin N; Tripier R; Halime Z; Haddad F; Faivre-Chauvet A; Kraeber-Bodéré F; Chérel M; Bodet-Milin C
    Oncotarget; 2018 Feb; 9(10):9061-9072. PubMed ID: 29507674
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Evaluation of the biological activities of the IL-15 superagonist complex, ALT-803, following intravenous versus subcutaneous administration in murine models.
    Liu B; Jones M; Kong L; Noel T; Jeng EK; Shi S; England CG; Alter S; Miller JS; Cai W; Rhode PR; Wong HC
    Cytokine; 2018 Jul; 107():105-112. PubMed ID: 29452720
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth.
    Delgado-Calle J; Anderson J; Cregor MD; Condon KW; Kuhstoss SA; Plotkin LI; Bellido T; Roodman GD
    Leukemia; 2017 Dec; 31(12):2686-2694. PubMed ID: 28529307
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Low intensity vibration mitigates tumor progression and protects bone quantity and quality in a murine model of myeloma.
    Pagnotti GM; Chan ME; Adler BJ; Shroyer KR; Rubin J; Bain SD; Rubin CT
    Bone; 2016 Sep; 90():69-79. PubMed ID: 27262776
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Preclinical animal models of multiple myeloma.
    Lwin ST; Edwards CM; Silbermann R
    Bonekey Rep; 2016; 5():772. PubMed ID: 26909147
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Perfusion Pressure Is a Critical Determinant of the Intratumoral Extravasation of Oncolytic Viruses.
    Miller A; Nace R; Ayala-Breton C C; Steele M; Bailey K; Peng KW; Russell SJ
    Mol Ther; 2016 Feb; 24(2):306-317. PubMed ID: 26647825
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Single-Dose Anti-CD138 Radioimmunotherapy: Bismuth-213 is More Efficient than Lutetium-177 for Treatment of Multiple Myeloma in a Preclinical Model.
    Fichou N; Gouard S; Maurel C; Barbet J; Ferrer L; Morgenstern A; Bruchertseifer F; Faivre-Chauvet A; Bigot-Corbel E; Davodeau F; Gaschet J; Chérel M
    Front Med (Lausanne); 2015; 2():76. PubMed ID: 26582128
    [TBL] [Abstract][Full Text] [Related]  

  • 80. PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma.
    Noll JE; Vandyke K; Hewett DR; Mrozik KM; Bala RJ; Williams SA; Kok CH; Zannettino AC
    J Hematol Oncol; 2015 Oct; 8():106. PubMed ID: 26445238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.